Stockreport

Arcellx to Advance the Conversation on Its Platform and the Importance of Early CAR T Access for Patients with Multiple Myeloma During the 2026 Tandem Meetings

Arcellx, Inc.  (ACLX) 
PDF -- The D-Domain binder has a fast off-rate and contributes to anito-cel’s differentiated pharmacology profile in multiple myeloma ---- A simulation model of CAR T use ah [Read more]